Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
OXYCONTIN vs SUMATRIPTAN; NAPROXEN SODIUM
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Oxycodone is a full opioid agonist with relative selectivity for the mu-opioid receptor, although it can bind to other opioid receptors at higher doses. The principal therapeutic action of oxycodone is analgesia. Like all full opioid agonists, there is no ceiling effect for analgesia with oxycodone. Clinically, dosage is titrated to provide adequate analgesia and may be limited by adverse reactions, including respiratory and CNS depression.
Sumatriptan is a selective 5-HT1B/1D receptor agonist, causing vasoconstriction of cranial blood vessels and inhibition of trigeminal nerve transmission. Naproxen sodium is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis.
Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate,Off-label: Treatment of opioid dependence (as part of substitution therapy)
Acute treatment of migraine attacks with or without aura in adults
10 mg orally every 12 hours; titrate based on pain severity and prior opioid exposure.
Sumatriptan 85 mg / naproxen sodium 500 mg orally at onset of migraine; may repeat once after 2 hours if needed, not to exceed 2 tablets in 24 hours.
4.5-5.0 hours (immediate-release); controlled-release OXYCONTIN has an apparent half-life of 4.5-8.7 hours. Terminal half-life is ~3.5-4 hours for immediate-release, reflecting context-sensitive elimination.
Sumatriptan: terminal half-life approximately 2.5 hours (range 1.5–4.6 hours); clinically, short half-life limits duration of action. Naproxen sodium: terminal half-life approximately 12–17 hours (mean 14 hours); long half-life allows twice-daily dosing and sustained analgesic effect.
Oxycodone is metabolized primarily via CYP3A4 to noroxycodone (major metabolite) and via CYP2D6 to oxymorphone (minor metabolite). Both metabolites are active, with oxymorphone having higher potency. Oxycodone and its metabolites are conjugated and excreted in urine.
Sumatriptan is primarily metabolized by monoamine oxidase A (MAO-A). Naproxen is metabolized by CYP2C9.
Primarily renal (90% as metabolites, 10% unchanged). Also biliary/fecal (10%).
Sumatriptan: renal excretion of unchanged drug and metabolites (primarily indole acetic acid analogue) accounts for approximately 60% of elimination; fecal/biliary excretion accounts for about 40%. Naproxen sodium: renal excretion of unchanged drug (approximately 60%) and glucuronide conjugates (about 40%); less than 5% is excreted fecally.
38-45%, primarily bound to albumin.
Sumatriptan: protein binding approximately 14–21% (low binding). Naproxen sodium: protein binding >99% (highly bound to albumin).
2.6-3.0 L/kg. Extensive tissue distribution, high Vd indicates penetration into peripheral tissues.
Sumatriptan: Vd approximately 2.2 L/kg (indicates extensive tissue distribution). Naproxen sodium: Vd approximately 0.16 L/kg (low Vd, consistent with high protein binding and limited tissue distribution).
Oral immediate-release: 60-87% (first-pass metabolism). Oral extended-release (Oxy Contin): 60-87% (similar). Intravenous: 100%.
Sumatriptan: oral bioavailability approximately 15% (due to first-pass metabolism); subcutaneous injection 96%; intranasal approximately 17%. Naproxen sodium: oral bioavailability >95% (well absorbed).
Cr Cl 30-60 m L/min: reduce dose by 25%; Cr Cl <30 m L/min: reduce dose by 50% and administer every 12 hours; hemodialysis: avoid use.
Contraindicated if GFR <30 m L/min; for GFR 30-50 m L/min, caution with naproxen component; no specific dose adjustment recommended for sumatriptan.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: avoid use.
Contraindicated in severe hepatic impairment (Child-Pugh class C); sumatriptan maximum dose 50 mg per dose in moderate impairment (Child-Pugh class B); naproxen sodium avoid in severe impairment.
Not approved for pediatric patients <18 years; for children ≥11 years (opioid-tolerant): 0.2 mg/kg orally every 12 hours, titrate; maximum single dose 10 mg.
Not approved for patients <12 years; for adolescents 12-17 years, single dose of sumatriptan 85 mg / naproxen sodium 500 mg (as adult formulation) per clinical judgment, not to exceed 1 dose in 24 hours.
Initiate at 5 mg orally every 12 hours; titrate cautiously; monitor for respiratory depression and constipation.
Avoid use in elderly due to increased risk of cardiovascular events, gastrointestinal bleeding, and renal impairment; if necessary, use lowest effective dose for shortest duration.
WARNING: ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME; and RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS
Cardiovascular and gastrointestinal risks: NSAIDs increase the risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. Risk increases with duration of use. NSAIDs also increase the risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. Sumatriptan is contraindicated in patients with history of coronary artery disease or risk factors. Do not use within 24 hours of another 5-HT1 agonist or ergotamine-containing medication.
Addiction, abuse, and misuse: Oxy Contin exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death. Assess each patient's risk prior to prescribing, and monitor all patients regularly for the development of these behaviors or conditions.,Life-threatening respiratory depression: Serious, life-threatening, or fatal respiratory depression may occur. Monitor for respiratory depression, especially during initiation of therapy or following a dose increase. Instruct patients to swallow tablets whole; crushing, chewing, or dissolving can cause rapid release and absorption of a potentially fatal dose.,Accidental ingestion: Accidental ingestion of even one dose of Oxy Contin, especially by children, can result in a fatal overdose of oxycodone.,Neonatal opioid withdrawal syndrome: Prolonged use of Oxy Contin during pregnancy can result in withdrawal in the neonate. Neonatal opioid withdrawal syndrome, unlike opioid withdrawal in adults, may be life-threatening if not recognized and treated.,Risks from concomitant use with benzodiazepines or other CNS depressants: Concomitant use of opioids with benzodiazepines or other CNS depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing for use in patients for whom alternative treatment options are inadequate.
Cardiovascular events: Myocardial ischemia, infarction, arrhythmia, and death reported with sumatriptan. NSAIDs increase risk of serious cardiovascular thrombotic events.,Gastrointestinal effects: NSAIDs increase risk of GI bleeding, ulceration, and perforation.,Excessive use: Medication overuse headache may occur.,Serotonin syndrome: Risk with concurrent use of serotonergic drugs.,Renal effects: NSAIDs can cause renal toxicity.,Hypertension: Sumatriptan may increase blood pressure.,Anaphylactic reactions: Serious allergic reactions including anaphylaxis reported with sumatriptan.,Hepatic effects: NSAIDs may cause liver enzyme elevations.
Significant respiratory depression,Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment,Known or suspected gastrointestinal obstruction, including paralytic ileus,Hypersensitivity (e.g., anaphylaxis) to oxycodone or any other components of the product
History of coronary artery disease (CAD) or coronary artery vasospasm,Wolff-Parkinson-White syndrome or other cardiac accessory pathway disorders,History of stroke or transient ischemic attack,Peripheral vascular disease,Ischemic bowel disease,Uncontrolled hypertension,Within 24 hours of treatment with another 5-HT1 agonist (e.g., triptans) or ergotamine-containing medications,Concomitant use or within 2 weeks of MAO-A inhibitor,History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs,In the setting of coronary artery bypass graft (CABG) surgery,Third trimester of pregnancy
Avoid alcohol, which can increase oxycodone absorption and central nervous system depression. Grapefruit juice may alter oxycodone metabolism; limit or avoid consumption. No specific food restrictions, but high-fat meals may slow absorption slightly; take with or without food consistently.
Avoid alcohol (may exacerbate migraine and increase GI irritation). Limit caffeine intake (can trigger migraine). No specific food restrictions, but maintain hydration.
FDA Pregnancy Category C prior to 2020; no adequate studies in pregnant women. First trimester: Limited data suggest possible increased risk of neural tube defects (1.8-fold) and oral clefts (1.5-fold) with opioid use, but confounded by underlying conditions. Second and third trimesters: Chronic use may cause fetal opioid dependence and neonatal abstinence syndrome (NAS); maternal withdrawal may precipitate preterm labor. Avoid prolonged use near term due to risk of neonatal respiratory depression.
Sumatriptan: Limited data; no increased risk of major congenital malformations observed in cohort studies. Avoid use in third trimester due to potential uterine vasoconstriction and reduced placental perfusion. Naproxen: First trimester – potential increased risk of cardiac defects; second trimester – generally safe with caution; third trimester – contraindicated due to risk of premature ductus arteriosus closure, oligohydramnios, and fetal renal dysfunction.
Oxycodone is excreted into breast milk; relative infant dose is approximately 2.7–8.8% of maternal weight-adjusted dose. M/P ratio unknown. Monitor infant for sedation, respiratory depression, and poor feeding. American Academy of Pediatrics considers oxycodone compatible with breastfeeding with caution; avoid rapid accumulation in mothers with impaired metabolism (CYP2D6 poor metabolizers).
Sumatriptan: Excreted in breast milk with estimated relative infant dose of 3.5% of maternal weight-adjusted dose; M/P ratio not well defined. Naproxen: Excreted in breast milk with M/P ratio approximately 0.01; relative infant dose <1% of maternal dose. Both considered compatible with breastfeeding with monitoring for infant adverse effects.
Pregnancy increases oxycodone clearance by 1.3- to 2.5-fold due to enhanced hepatic metabolism (CYP3A4 and CYP2D6 induction) and increased renal blood flow. Dose adjustments may be necessary to maintain analgesia; clinical monitoring for pain control and withdrawal symptoms is essential. Titrate to effect; avoid abrupt discontinuation. Postpartum clearance returns to baseline over 1-2 weeks.
No specific dose adjustments recommended for sumatriptan in pregnancy; however, limited data suggest no significant pharmacokinetic changes. Naproxen: Clearance may increase in later pregnancy; dose adjustments not well studied. Avoid naproxen in third trimester.
Oxy Contin is an extended-release formulation of oxycodone, indicated for around-the-clock pain management. Do not crush, chew, or break tablets, as this can lead to rapid release and fatal overdose. Use with caution in patients with respiratory compromise, head injury, or increased intracranial pressure. Monitor for signs of misuse, abuse, or addiction. Abrupt discontinuation may precipitate withdrawal; taper dose gradually. Constipation is common; consider prophylactic laxatives. Contraindicated in severe asthma, paralytic ileus, or hypersensitivity.
Sumatriptan/naproxen sodium is contraindicated within 24 hours of another triptan or ergotamine. Naproxen dose is fixed; avoid additional NSAIDs to prevent GI bleeding or renal impairment. Use with caution in patients with cardiovascular risk factors. Onset of action is 10-30 minutes; advise against driving if dizziness occurs.
Take Oxy Contin exactly as prescribed, usually every 12 hours. Do not take more or less than directed.,Swallow the tablet whole with water. Do not crush, chew, or break the tablet, as this can cause a dangerous overdose.,Avoid alcohol and other central nervous system depressants (e.g., benzodiazepines, sedatives) as they increase the risk of severe sedation, respiratory depression, and death.,Do not stop taking Oxy Contin suddenly; ask your doctor how to safely discontinue the medication to avoid withdrawal symptoms.,Common side effects include constipation, nausea, drowsiness, and dizziness. Contact your doctor if you experience severe constipation, difficulty breathing, or signs of allergic reaction.,Store Oxy Contin in a secure place out of sight and reach of children and pets. Dispose of unused medication via a drug take-back program.,Do not drive or operate heavy machinery until you know how Oxy Contin affects you.,Inform all healthcare providers that you are taking Oxy Contin, especially before surgery or emergency treatment.
Take at the first sign of migraine; do not exceed one tablet in 24 hours.,Do not take within 24 hours of other triptans or ergotamine-containing drugs.,Avoid alcohol during migraine attack as it may worsen symptoms.,Report chest tightness, palpitations, or shortness of breath immediately.,Do not drive or operate machinery if feeling dizzy or drowsy.,Inform healthcare provider of all medications, especially blood thinners or antidepressants.
No interactions on record
"Naproxen and meloxicam are both nonsteroidal anti-inflammatory drugs (NSAIDs) that inhibit cyclooxygenase (COX) enzymes, leading to decreased synthesis of prostaglandins, prostacyclin, and thromboxanes. Concomitant use increases the risk of dose-dependent adverse effects, particularly gastrointestinal ulceration, bleeding, and perforation, as well as renal impairment, due to additive inhibition of protective prostaglandins in the gut and kidney. Clinically, this combination may result in acute kidney injury, anemia from occult gastrointestinal bleeding, or life-threatening perforation, especially in elderly patients or those with pre-existing renal disease or peptic ulcer history."
"Bevantolol, a beta-1 selective adrenergic receptor antagonist, reduces cardiac output and suppresses renin release, thereby lowering blood pressure. Naproxen, a nonsteroidal anti-inflammatory drug (NSAID), inhibits cyclooxygenase (COX) enzymes, leading to decreased synthesis of vasodilatory prostaglandins and enhanced sodium and water retention. The net effect is an attenuation of bevantolol's antihypertensive efficacy, potentially resulting in elevated blood pressure and reduced cardiovascular protection."
"Betaxolol, a beta-1 selective adrenergic receptor antagonist, may reduce the antihypertensive efficacy of naproxen, a nonsteroidal anti-inflammatory drug (NSAID). Naproxen inhibits cyclooxygenase (COX) enzymes, leading to decreased synthesis of vasodilatory prostaglandins (e.g., prostacyclin) in the renal and vascular endothelium. This can result in sodium and fluid retention, increased systemic vascular resistance, and blunting of the blood pressure-lowering effects of beta-blockers like betaxolol, potentially compromising hypertension control."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about OXYCONTIN vs SUMATRIPTAN; NAPROXEN SODIUM, answered by our medical review team.
OXYCONTIN is a Opioid Analgesic that works by Oxycodone is a full opioid agonist with relative selectivity for the mu-opioid receptor, although it can bind to other opioid receptors at higher doses. The principal therapeutic action of oxycodone is analgesia. Like all full opioid agonists, there is no ceiling effect for analgesia with oxycodone. Clinically, dosage is titrated to provide adequate analgesia and may be limited by adverse reactions, including respiratory and CNS depression.. SUMATRIPTAN; NAPROXEN SODIUM is a 5-HT1 Agonist that works by Sumatriptan is a selective 5-HT1B/1D receptor agonist, causing vasoconstriction of cranial blood vessels and inhibition of trigeminal nerve transmission. Naproxen sodium is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between OXYCONTIN and SUMATRIPTAN; NAPROXEN SODIUM depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of OXYCONTIN is: 10 mg orally every 12 hours; titrate based on pain severity and prior opioid exposure.. The standard adult dose of SUMATRIPTAN; NAPROXEN SODIUM is: Sumatriptan 85 mg / naproxen sodium 500 mg orally at onset of migraine; may repeat once after 2 hours if needed, not to exceed 2 tablets in 24 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between OXYCONTIN and SUMATRIPTAN; NAPROXEN SODIUM in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. OXYCONTIN is classified as Category C. FDA Pregnancy Category C prior to 2020; no adequate studies in pregnant women. First trimester: Limited data suggest possible increased risk of neural tube defects (1.8-fold) and o. SUMATRIPTAN; NAPROXEN SODIUM is classified as Category D/X. Sumatriptan: Limited data; no increased risk of major congenital malformations observed in cohort studies. Avoid use in third trimester due to potential uterine vasoconstriction an. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.